Natap is reporting many results from EASL 2023. Please read the full report from Natap/Easl. I am just posting the summary:
Patients with chronic HBV treated with TAF only and those who switched from TDF to TAF over 8 years demonstrated:
-High rates of persistent viral suppression (91%-98%)
-High rates of ALT normalization were achieved early and maintained with TAF, while ALT normalization increased in TDF-treated patients switched to TAF in the OL period
-With long-term TAF treatment in HBeAg-positive patients, the rates of HBeAg loss and seroconversion increased progressively(approximately 45% and 30%, respectively)
-In patients with cirrhosis based on Fibro Test at baseline, the majority showed improvement in fibrosis with long-term treatment
-No resistance to TAF was observed.
Treatment with TAF was highly effective in patients with chronic HBV. These results provide support for TAF as the preferred treatment for chronic HBV infection.